Healthcare >> Analyst Interviews >> May 8, 2002
SRINIVAS AKKARAJU joined the Life Sciences team in the Healthcare Group
at J.P. Morgan Partners, LLC, in April 2001. From October 1998 to April
2001, he was in the Business and Corporate Development Group at
Genentech, Inc., most recently as Senior Manager. There Dr. Akkaraju was
responsible for worldwide partnering activities including technology
access deals, in-licensing of early and late-stage therapeutics, and
out-licensing of Genentech development projects. In addition to his
business development role, he also served for the last year as Project
Team Leader for one of Genentech's clinical development products. During
this time, Dr. Akkaraju was also a founding member of BioStreet, an
online marketplace for biotech opportunities. Prior to joining Genentech
in 1998, Dr. Akkaraju was a graduate student at Stanford University,
where he earned his MD and PhD in Immunology. Dr. Akkaraju earned his
undergraduate degrees in Biochemistry and Computer Science from Rice
University in 1990. Profile
the key trends right now that investors should focus on?
Dr. Akkaraju: One of the key trends of the industry overall has
been
